HIV/AIDS Topics HIV Treatment HIV Drug Resistance
CROI 2013: Transmitted Antiretroviral Drug Resistance Holds Steady at 16% [VIDEO]
- Details
- Category: HIV Treatment
- Published on Monday, 25 March 2013 00:00
- Written by Gregory Fowler
Approximately 1 in 6 analyzed HIV sequences showed evidence of antiretroviral drug resistance, with NNRTIs being particularly vulnerable, according to a CDC analysis presented at the recent 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.
CROI 2013: Dolutegravir Helps Highly-resistant Treatment-experienced People on Failing ART
- Details
- Category: HIV Treatment
- Published on Friday, 08 March 2013 00:00
- Written by Liz Highleyman
The next-generation integrase inhibitor dolutegravir proved more beneficial than raltegravir (Isentress) for highly treatment-experienced people with resistance to 2 or more antiretroviral drug classes, researchers reported in a poster presented at the20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) this week in Atlanta.
ICAAC: New Integrase Inhibitor BI 224436 Active against Raltegravir-Resistant HIV
- Details
- Category: HIV Treatment
- Published on Friday, 07 October 2011 00:00
- Written by Liz Highleyman
Boehringer Ingelheim's novel integrase inhibitor candidate BI 2244336, which works by a different mechanism than existing drugs in its class, demonstrated potent antiviral activity and a good pharmacokinetic profile in a series of early studies presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2011) last month in Chicago.
CROI 2013: Can People with Resistant HIV Omit NRTIs When Switching to a New Regimen? [VIDEO]
- Details
- Category: HIV Treatment
- Published on Thursday, 07 March 2013 00:00
- Written by Gregory Fowler
Omitting nucleoside reverse transcriptase inhibitors (NRTIs) when switching from a non-suppressive regimen to a new combination with at least 2 active agents can reduce pill burden and side effects without compromising effectiveness, researchers reported yesterday at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.
ICAAC: Declining Prevalence of HIV Triple-class and Protease Inhibitor Resistance
- Details
- Category: HIV Treatment
- Published on Friday, 07 October 2011 00:00
- Written by Liz Highleyman
HIV strains showing resistance to protease inhibitors, or to all 3 of the earliest classes of antiretroviral drugs, have become less common over the past several years, making it easier to construct effective regimens, researchers reported at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2011) last month in Chicago.
Dolutegravir Active against Raltegravir-resistant HIV, Granted FDA Priority Review
- Details
- Category: HIV Treatment
- Published on Wednesday, 20 February 2013 00:00
- Written by Liz Highleyman
ViiV Healthcare announced last week that the U.S. Food and Drug Administration has given a priority review designation for its investigational HIV integrase inhibitor dolutegravir, which has demonstrated good efficacy in both treatment-naive and treatment-experienced people.
Darunavir/Ritonavir plus Raltegravir May Not Adequately Suppress High Viral Load
- Details
- Category: HIV Treatment
- Published on Tuesday, 06 September 2011 00:00
- Written by Liz Highleyman
People with high baseline HIV viral load who used a NRTI-sparing regimen of ritonavir-boosted darunavir (Prezista) plus raltegravir (Isentress) had a higher than expected rate of virological failure and emergence of drug resistance mutations, according to research reported in the August 19, 2011, advance online edition of AIDS.
More Articles...
- Raltegravir Resistance Can Emerge with Low Viral Load
- Uncommon Resistance Mutations Can Cause First-Line Treatment Failure
- Another Report of Drug-resistant HIV in a Patient Treated with Entecavir (Baraclude) for Hepatitis B
- Another Report of Drug-resistant HIV in a Patient Treated with Entecavir (Baraclude) for Hepatitis B
- Another Report of Drug-resistant HIV in a Patient Treated with Entecavir (Baraclude) for Hepatitis B
- Another Report of Drug-resistant HIV in a Patient Treated with Entecavir (Baraclude) for Hepatitis B
- Another Report of Drug-resistant HIV in a Patient Treated with Entecavir (Baraclude) for Hepatitis B
- Another Report of Drug-resistant HIV in a Patient Treated with Entecavir (Baraclude) for Hepatitis B
- Another Report of Drug-resistant HIV in a Patient Treated with Entecavir (Baraclude) for Hepatitis B
- Another Report of Drug-resistant HIV in a Patient Treated with Entecavir (Baraclude) for Hepatitis B
Web Design and Development by